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Introduction: Pachydermoperiostosis is a rare, hereditary disease commonly presenting with digital clubbing,
pachydermia and periosteal hypertrophy. Therapeutic options for pachydermoperiostosis are few because of the
unknown pathogenesis. Here, we report the complicated case of a patient with pachydermoperiostosis combined
with spondyloarthritides, who was refractory to steroids and tumor necrosis factor alpha antagonists. We treated
this patient with zoledronic acid and performed an arthroscopic synovectomy, with a satisfactory outcome. To the
best of our knowledge, this is the first report in English on the combination of zoledronic acid administration and
synovectomy for the treatment of a patient with pachydermoperiostosis and spondyloarthritides.
Case presentation: An 18-year-old Han Chinese man was diagnosed with pachydermoperiostosis in the presence
of digital clubbing, periostitis and swollen limbs. Combined spondyloarthritides was also considered based on his
lower back pain, lower limbs synovitis, bilateral sacroiliac sclerosis and a positive test for human leukocyte antigen B27,
as well as immunoglobulin A nephropathy. He was refractory to steroids and tumor necrosis factor alpha antagonists,
but treated with intravenous zoledronic acid and an arthroscopic synovectomy, with a satisfactory outcome.
Conclusion: This is a rare, complicated case of pachydermoperiostosis with spondyloarthritides. Combination therapy
of zoledronic acid administration with synovectomy is a novel, convenient and effective option for patients with
pachydermoperiostosis with remarkable synovitis.
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Pachydermoperiostosis is a rare, hereditary disease com-
monly presenting with digital clubbing, pachydermia and
periosteal hypertrophy [1]. In the past couple of decades,
there have been several reports and some research aimed
at finding more effective treatment methods for this
disease. We report the complicated case of a patient
with pachydermoperiostosis and spondyloarthritides
who was refractory to steroids and tumor necrosis factor
alpha (TNF-α) antagonists, treated by administration of
zoledronic acid and an arthroscopic synovectomy with a
satisfactory outcome. To the best of our knowledge, this is
the first report in English of a combination of zoledronic* Correspondence: shenmpumch@163.com
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reproduction in any medium, provided the oracid administration and a synovectomy for pachydermo-
periostosis therapy.
Case presentation
An 18-year-old Han Chinese man presented to our
hospital with a two-year history of pain and swelling in
multiple joints, with facial changes of one year duration.
In the winter of 2008 he began to experience joint
pain involving his knees, ankles, hips and the small
joints of his hands with obvious swollen knees and
ankles. Gradually, he developed difficulty squatting and
clenching his fists, as well as lower back pain with
morning stiffness. He denied fever, weight loss, eye
diseases or inflammatory bowel diseases. He was diag-
nosed with spondyloarthritides and treated with steroids,
salicylazosulfapyridine, loxoprofen sodium and infliximab,
but without positive effects. In April 2009, minimal pro-
teinuria and hematuria were found. A kidney biopsy
showed immunoglobulin A (IgA) nephropathy with a Lee’s
classification of Grade I. He further developed overt facialLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of his facial, scalpel and plantar skin, hyperhidrosis and
enlargement of his hands and feet with digital clubbing
(Figure 1).
A physical examination found no limitation of his chest
expansion or lumbar spine mobility. A serum investigation
showed a two-fold elevation of erythrocyte sedimentation
rate (ESR) and a 10-fold elevation of C-reactive protein
(CRP); he was negative for rheumatoid factor and positive
for human leukocyte antigen B27. An ultrasound of his
knees indicated synovitis. Joint effusion showed inflam-
mation with a negative culture result. Radiographs of
his hands and feet demonstrated marked clubbing with
mushrooming of the tufts (Figure 2). Periostosis was
detected in his tibiae and fibulae, limited to the diaphysis,
with a monolayer configuration. A sacroiliac computed
tomography scan revealed bilateral blur and sclerosis
with widened joint gaps.
After admission to our hospital, our patient was di-
agnosed with pachydermoperiostosis complicated by
spondyloarthritides, and given prednisone 50mg/day,
methotrexate 15mg/week and salicylazosulfapyridine
2g/day, as well as calcium and alendronic acid 70mg/
week. This combined therapy yielded a poor response.
He was then administered intravenous zoledronic acid
and we performed a synovectomy on both knee joints,
with prednisone tapered rapidly over the following
two weeks. His symptoms improved remarkably, with
an assessment of pain intensity recorded on a 10cm
visual analogue scale decreasing from 8 to 1. His ESR
and levels of CRP also decreased to normal. Our
patient recovered and remains well six months after
discharge.Figure 1 Enlargement of the hands with digital clubbing.Discussion
Pachydermoperiostosis is one of the conditions that makes
up the primary hypertrophic osteoarthropathy (HOA)
group, and is a rare hereditary disease occurring pre-
dominantly in men. Clinical symptoms include the
‘HOA triad’ of digital clubbing, periostitis and swollen
limbs. Periostosis shown in radiographs is also used
in the diagnosis of HOA. Elevated ESR and CRP with
synovitis might be found in patients with pachyder-
moperiostosis, yet it is fairly rare to note a two-fold
elevation of ESR and a 10-fold elevation of CRP. Our
patient had lower back pain with morning stiffness,
lower limb joints synovitis and bilateral sacroiliac
sclerosis, plus was positive for human leukocyte antigen
B27. IgA nephropathy is common in patients with
spondyloarthritides, but there is no such association in
pachydermoperiostosis. A diagnosis of spondyloarthritides
based on IgA nephropathy is thus considered reasonable.
The failure to respond to TNF antagonists might be
because this sclerosing bone-forming phenotype of
spondyloarthropathy is less responsive to TNF antagonists
than other more inflammatory phenotypes. Moreover,
a good response to zoledronic acid in patients with
spondyloarthritides has previously been described [2].
Considering all these factors, our patient was finally
diagnosed with pachydermoperiostosis complicated with
spondyloarthritides, plus IgA nephropathy. Only one case
of pachydermoperiostosis associated with spondyloarthri-
tides has previously been reported [3], which may have
been a coincidence, but an association between these two
diseases could cause diagnostic problems.
There are several possible etiological factors for pachy-
dermoperiostosis, such as genetic aberration, fibroblast
Figure 2 X-ray images of the hands disclosed widening of the epiphysis.
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osteoblastic activity and excess fibroblast proliferation.
But therapeutic options for pachydermoperiostosis are
few because of the unknown pathogenesis. Conventional
drugs like non-steroidal anti-inflammatory drugs, pain-
killers and colchicine [4] are usually the first-line drugs.
Plastic surgery can be an option for patients with re-
markable facial changes. We considered that reducing the
inflammatory component and the osteoclastic or osteo-
blastic activity might be an effective therapy. Nevertheless,
steroids, disease-modifying anti-rheumatic drugs and
infliximab all failed in our patient.
Although several case studies have reported that par-
enteral bisphosphonates can reduce pain and other
symptoms related to HOA [4-6], alendronic acid was tried
in our patient without response. In one study, pamidro-
nate resulted in a significant reduction of pain in three
patients with HOA. In other studies, zoledronic acid
was shown to be effective [7-9]. We treated our patient
with intravenous zoledronic acid and noted a rapid re-
mission with no adverse events. Compared with other
bisphosphonates, zoledronic acid is novel, effective and
more convenient. Long-term follow-up should be recom-
mended. The mechanism of action of bisphosphonates
in HOA remains unclear but it is commonly accepted
that they have both anti-resorptive and anti-inflammatory
benefits [7].
There were also several reports of patients with pachy-
dermoperiostosis treated with synovectomy [5]. Withregard to an associated obvious synovitis and refractory
elevated ESR and CRP, a synovectomy was carried out
in our patient. Post-surgical levels of ESR and CRP de-
creased to normal ranges. It appears that synovectomy
is effective in the obvious inflammatory reaction in
pachydermoperiostosis, both for local and systemic
inflammation.
Conclusion
This is a complicated case of a patient with pachydermo-
periostosis with spondyloarthritides and IgA nephropathy.
We highlight the difficulties encountered in the clinical
practice of diagnosis and treatment. A combination ther-
apy of zoledronic acid administration and synovectomy is
a novel, convenient and effective option for patients with
pachydermoperiostosis with remarkable synovitis.
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